The US Food and Drug Administration (FDA) has approved a new drug for the treatment of adult and child cancer based on genetic mutations based on the type of illness.
The drug called Vitrakvi and his name have been renamed the LAROTECTINIB scientific name for treating cancer that occurs anywhere in the body.
NITCAVI is the first drug designed to tackle genetic mutation of the disease, regardless of the type of cancer, said NBC.
Approval of the FDA is an important step in the treatment of cancer, "said FDA Commissioner Scott Gottlieb in a statement." Basis of tumor genes in any case of the body. "
"This will help the patient" provide the right treatment ", he said.
Drugs treat people of different tumors, but they have a common genetic mutation and have not been available for decades, said that there was a growing awareness of genetic mutations.